Evidence map›Paper›PMID 29216901›Full record

ArticleHuman genomics2017

Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients.

Konstantinos Mitropoulos, Eleni Merkouri Papadima, Georgia Xiromerisiou, Angeliki Balasopoulou, Kyriaki Charalampidou, Vasiliki Galani, Krystallia-Vassiliki Zafeiri, Efthymios Dardiotis, Styliani Ralli, Georgia Deretzi and 23 more

Open access · goldAbstract read
In one paragraph

Article in Human genomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.Journal of molecular neuroscience : MN · 2018
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. The Maternal Microbiome Programs the mFrontiers in cell and developmental biology · 2022
    Article
  10. Article
  11. Emerging Role of mFrontiers in cell and developmental biology · 2021
    Review
  12. Article
  13. New Insights on the Role ofFrontiers in molecular biosciences · 2020
    Review
  14. ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 12 institutions in 7 countries.

Konstantinos MitropoulosNational and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Eleni Merkouri PapadimaDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Georgia XiromerisiouSchool of Medicine, University of Thessaly, Larisa, Greece.
Angeliki BalasopoulouDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Kyriaki CharalampidouDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Vasiliki GalaniDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Krystallia-Vassiliki ZafeiriDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Efthymios DardiotisSchool of Medicine, University of Thessaly, Larisa, Greece.
Styliani RalliSchool of Medicine, University of Thessaly, Larisa, Greece.
Georgia DeretziPapageorgiou hospital, Thessaloniki, Greece.
Anne JohnDepartment of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, UAE.
Kyriaki KydonopoulouANALYSI Diagnostic Laboratories S.A, Thessaloniki, Greece.
Elpida PapadopoulouANALYSI Diagnostic Laboratories S.A, Thessaloniki, Greece.
Alba di PardoDepartments of Neurology and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Fulya AkcimenSuna and Inan Kirac Foundation, NDAL, Bogazici University, Istanbul, Turkey.
Annalisa LoizeddaDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Valerija DobričićInstitute of Neurology CCS, School of Medicine, University of Belgrade, Belgrade, Serbia.
Ivana NovakovićInstitute of Neurology CCS, School of Medicine, University of Belgrade, Belgrade, Serbia.
Vladimir S KostićInstitute of Neurology CCS, School of Medicine, University of Belgrade, Belgrade, Serbia.
Clint MizziDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Brock A PetersComplete Genomics Inc., Mountain View, CA, USA.
Nazli BasakSuna and Inan Kirac Foundation, NDAL, Bogazici University, Istanbul, Turkey.
Sandro OrrùDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Evangelos KiskinisDepartments of Neurology and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
David N CooperInstitute of Medical Genetics, Cardiff University, Cardiff, UK.
Spyridon GerouANALYSI Diagnostic Laboratories S.A, Thessaloniki, Greece.
Radoje DrmanacComplete Genomics Inc., Mountain View, CA, USA.
Marina BartsakouliaDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Evangelia-Eirini TsermpiniDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
Georgios M HadjigeorgiouSchool of Medicine, University of Thessaly, Larisa, Greece.
Bassam R AliDepartment of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, UAE.
Theodora KatsilaDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece.
George P PatrinosDepartment of Pharmacy, University of Patras School of Health Sciences, Campus, Rion, GR-26504, Patras, Greece. gpatrinos@upatras.gr.
University of Patras · GRUniversity of Thessaly · GRUnited Arab Emirates University · AEUniversity of Belgrade · RSBoğaziçi University · TRComplete Genomics (United States) · USNorthwestern University · USCardiff University · GBInstitute of Genetic and Biomedical Research · ITNational and Kapodistrian University of Athens · GRPapageorgiou General Hospital · GRUniversity of Cagliari · IT

Funding

General Secretariat of Research and Technology 11_046Horizon 2020 Framework Programme 668353Seventh Framework Programme 305444
6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is a devastating disease whose complex pathology has been associated with a strong genetic component in the context of both familial and sporadic disease. Herein, we adopted a next-generation sequencing approach to Greek patients suffering from sporadic ALS (together with their healthy counterparts) in order to explore further the genetic basis of sporadic ALS (sALS).

resultsWhole-genome sequencing analysis of Greek sALS patients revealed a positive association between FTO and TBC1D1 gene variants and sALS. Further, linkage disequilibrium analyses were suggestive of a specific disease-associated haplotype for FTO gene variants. Genotyping for these variants was performed in Greek, Sardinian, and Turkish sALS patients. A lack of association between FTO and TBC1D1 variants and sALS in patients of Sardinian and Turkish descent may suggest a founder effect in the Greek population. FTO was found to be highly expressed in motor neurons, while in silico analyses predicted an impact on FTO and TBC1D1 mRNA splicing for the genomic variants in question.

conclusionsTo our knowledge, this is the first study to present a possible association between FTO gene variants and the genetic etiology of sALS. In addition, the next-generation sequencing-based genomics approach coupled with the two-step validation strategy described herein has the potential to be applied to other types of human complex genetic disorders in order to identify variants of clinical significance.

Indexed as

Alpha-Ketoglutarate-Dependent Dioxygenase FTOAmyotrophic Lateral SclerosisCase-Control StudiesComputer SimulationFounder EffectGreeceGTPase-Activating ProteinsHaplotypesHumansLinkage DisequilibriumMotor NeuronsPolymorphism, Single NucleotideAlpha-Ketoglutarate-Dependent Dioxygenase FTOFTO protein, humanGTPase-Activating ProteinsTBC1D1 protein, humanFounder populationFTO geneGenomic variantsSporadic amyotrophic lateral sclerosisWhole-genome sequencing

Identifiers

PMID29216901
PMCPMC5721583
OpenAlexW2773937672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.